Para fornecer o conteúdo mais relevante aos leitores do HealthCare Business News, pedimos que você compartilhe um pouco de informação sobre quem você é (leva dois segundos e pronto).
Registo
NAPT welcomes CMS rule to improve prior authorization, remains committed to further improving patient access to proton therapy
January 18, 2024 – The National Association for Proton Therapy (NAPT), the nation’s leading organization dedicated to increasing patient access to one of the most advanced cancer treatments, commends CMS for ensuring seniors have timely access to medical care, especially advanced cancer treatments, through the Advancing Interoperability and Improving Prior Authorization Processes (e-PA) Rule.
The final rule requires that beginning in 2026, Medicare Advantage (MA) plans must convey PA determinations within 72 hours for expedited requests and seven days for standard requests. MA plans must also detail a specific reason for denying a PA appeal and report PA metrics as part of new transparency and reporting requirements.
“For Medicare beneficiaries who need proton therapy and other advanced cancer treatments, prior authorizations create a burdensome process that often delays life-saving treatment,” said NAPT Executive Director Jennifer Maggiore. “This new rule puts payors on notice that CMS is serious about removing barriers to care and sparing patients the frustrating and potentially harmful experience of waiting days or weeks for a coverage decision.”
According to data released by NAPT, the burden of prior authorizations is steadily increasing among proton therapy centers. In a 2022 survey, it was revealed that 64 percent of patients referred for proton therapy experienced an average wait time of more than five days for prior authorization requests, a notable rise from 48.1 percent in 2021. In addition, 22 percent of these patients faced an average wait time of over 11 days, up from 14.7 percent in the previous year. These delays can be a matter of life and death, as evidenced by a 2019 Cleveland Clinic study that linked each week of treatment delay to a 1.2-3.2 percent increased risk of death among cancer patients.
In a recent survey conducted by the American Society of Clinical Oncology (ASCO), their members reported that a majority of their patients have experienced harm due to prior authorization processes with 96% reporting delays in treatment and 94% of patients forced to receive second-choice therapy. Another survey, in 2018 by the American Society for Radiation Oncology (ASTRO), found that 93 percent of radiation oncologists had encountered patient treatment delays due to prior authorizations, with 31 percent reporting delays lasting more than five days – equivalent to a full week of standard radiation treatment.
